{"id":"W4386074702","doi":"10.1097/01.hs9.0000971004.26914.cb","title":"P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Discontinuation; Phases of clinical research; Clinical endpoint; Gastroenterology; Oncology; Bone marrow; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002466868,0.0005721132,0.001686925,0.0005127068,0.0002884403,0.001466423,0.0006440728,0.0009477255,0.004274595],"category_scores_gemma":[0.00211086,0.0002539159,0.001617554,0.0007328402,0.0002517925,0.0009088023,0.0003611266,0.001876295,0.0009989333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009334517,"about_ca_system_score_gemma":0.0007757894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005543494,"about_ca_topic_score_gemma":0.001768381,"domain_scores_codex":[0.9992474,0.0002889455,0.0001033195,0.00009665806,0.0001811898,0.00008253013],"domain_scores_gemma":[0.9978673,0.0004483656,0.000953942,0.0001294056,0.0002996731,0.0003013045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3196224,0.005227315,0.0675997,0.005043425,0.006738796,0.0005406495,0.0002611805,0.002930238,0.02688458,0.0004999221,0.04626725,0.5183845],"study_design_scores_gemma":[0.1893374,0.2231186,0.4658785,0.001628893,0.01328887,0.003480262,0.0002586448,0.005380167,0.01455358,0.001303132,0.08157469,0.0001972278],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9134011,0.04521153,0.001282688,0.003275599,0.000531327,0.001313505,0.02070662,0.0005467284,0.01373078],"genre_scores_gemma":[0.9480463,0.01148361,0.00154952,0.003690588,0.0009376492,0.001002494,0.02906512,0.00008085153,0.004143752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004274595,"threshold_uncertainty_score":0.01429999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.012602810886682,"score_gpt":0.2505186048097666,"score_spread":0.2379157939230846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}